Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2025)

Mangoceuticals' Net Income towards Common Stockholders history spans 3 years, with the latest figure at -$7.9 million for Q3 2025.

  • For Q3 2025, Net Income towards Common Stockholders fell 295.7% year-over-year to -$7.9 million; the TTM value through Sep 2025 reached -$20.1 million, down 115.69%, while the annual FY2024 figure was -$8.7 million, 5.48% up from the prior year.
  • Net Income towards Common Stockholders for Q3 2025 was -$7.9 million at Mangoceuticals, down from -$5.4 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$1.8 million in Q3 2023 and bottomed at -$7.9 million in Q3 2025.
  • The 3-year median for Net Income towards Common Stockholders is -$2.4 million (2024), against an average of -$3.3 million.
  • The largest annual shift saw Net Income towards Common Stockholders rose 24.12% in 2024 before it plummeted 295.7% in 2025.
  • A 3-year view of Net Income towards Common Stockholders shows it stood at -$2.6 million in 2023, then grew by 24.12% to -$1.9 million in 2024, then crashed by 306.08% to -$7.9 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Net Income towards Common Stockholders are -$7.9 million (Q3 2025), -$5.4 million (Q2 2025), and -$4.8 million (Q1 2025).